PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

被引：38

作者：

Banerjee, Susana ^{[2
]}

Kaye, Stan ^{[1
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Div Clin Studies, Inst Canc Res, Drug Dev Unit, Sutton SM2 5PT, Surrey, England

[2] Royal Marsden NHS Fdn Trust, Gynaecol Unit, Sutton SM2 5PT, Surrey, England

来源：

CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 06期

关键词：

PARP inhibitors; Ovarian cancer; BRCA; Olaparib; Endometrial; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; MUTANT-CELLS; TUMOR; MUTATIONS; CARCINOMA; FEATURES; DELETION; REPAIR;

D O I：

10.1007/s11912-011-0193-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.

引用

页码：442 / 449

页数：8

共 50 条

[31] Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors [J].

Aliyuda, Fine ;

Moschetta, Michele ;

Ghose, Aruni ;

Rallis, Kathrine Sofia ;

Sheriff, Matin ;

Sanchez, Elisabet ;

Rassy, Elie ;

Boussios, Stergios .

CURRENT CANCER DRUG TARGETS, 2023, 23 (06) :433-446

[32] Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review [J].

Tao, Mengyu ;

Cheng, Jiejun ;

Wu, Xia .

ONCOTARGETS AND THERAPY, 2020, 13 :12979-12986

[33] PARP inhibitors in ovarian cancer: Current status and future promise [J].

Liu, Joyce F. ;

Konstantinopoulos, Panagiotis A. ;

Matulonis, Ursula A. .

GYNECOLOGIC ONCOLOGY, 2014, 133 (02) :362-369

[34] The Current Landscape of PARP Inhibitors in Ovarian Cancer [J].

Gunderson, Camille C. ;

Erickson, Britt K. ;

Buechel, Megan E. ;

Moore, Kathleen N. .

CURRENT OBSTETRICS AND GYNECOLOGY REPORTS, 2018, 7 (01) :20-27

[35] The current status of PARP inhibitors in ovarian cancer [J].

McLachlan, Jennifer ;

George, Angela ;

Banerjee, Susana .

TUMORI JOURNAL, 2016, 102 (05) :433-440

[36] The Current Landscape of PARP Inhibitors in Ovarian Cancer [J].

Camille C. Gunderson ;

Britt K. Erickson ;

Megan E. Buechel ;

Kathleen N. Moore .

Current Obstetrics and Gynecology Reports, 2018, 7 (1) :20-27

[37] Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors [J].

Musacchio, Lucia ;

Boccia, Serena ;

Marchetti, Claudia ;

Minucci, Angelo ;

Camarda, Floriana ;

Cassani, Chiara ;

Ventriglia, Jole ;

Salutari, Vanda ;

Ghizzoni, Viola ;

Giudice, Elena ;

Perri, Maria Teresa ;

Carbone, Maria Vittoria ;

Ricci, Caterina ;

Pignata, Sandro ;

Fagotti, Anna ;

Scambia, Giovanni ;

Lorusso, Domenica .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (06) :922-928

[38] PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions [J].

G E Konecny ;

R S Kristeleit .

British Journal of Cancer, 2016, 115 :1157-1173

[39] PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions [J].

Konecny, G. E. ;

Kristeleit, R. S. .

BRITISH JOURNAL OF CANCER, 2016, 115 (10) :1157-1173

[40] PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival [J].

Shao, Fengping ;

Duan, Yaoyun ;

Zhao, Yunhe ;

Li, Yinguang ;

Liu, Jun ;

Zhang, Cai ;

He, Shanyang .

AGING-US, 2021, 13 (06) :8975-8988

← 1 2 3 4 5 →